Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Purple Biotech (PPBT) Debt to Equity (2017 - 2020)

Purple Biotech has reported Debt to Equity over the past 4 years, most recently at $0.43 for Q2 2020.

  • Quarterly Debt to Equity rose 102.83% to $0.43 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $0.43 through Jun 2020, up 102.83% year-over-year, with the annual reading at $0.05 for FY2018, 78.26% down from the prior year.
  • Debt to Equity was $0.43 for Q2 2020 at Purple Biotech, up from $0.21 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.43 in Q2 2020 and troughed at $0.05 in Q4 2018.
  • The 4-year median for Debt to Equity is $0.22 (2019), against an average of $0.24.
  • The largest YoY upside for Debt to Equity was 405.06% in 2018 against a maximum downside of 78.26% in 2018.
  • A 4-year view of Debt to Equity shows it stood at $0.23 in 2017, then tumbled by 78.26% to $0.05 in 2018, then surged by 325.63% to $0.21 in 2019, then soared by 102.83% to $0.43 in 2020.
  • Per Business Quant, the three most recent readings for PPBT's Debt to Equity are $0.43 (Q2 2020), $0.21 (Q2 2019), and $0.05 (Q4 2018).